Evolutionary Genomics Stock Market Value
| FNAM Stock | USD 0.0002 0.00 0.00% |
| Symbol | Evolutionary |
Evolutionary Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Evolutionary Genomics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Evolutionary Genomics.
| 04/28/2025 |
| 07/27/2025 |
If you would invest 0.00 in Evolutionary Genomics on April 28, 2025 and sell it all today you would earn a total of 0.00 from holding Evolutionary Genomics or generate 0.0% return on investment in Evolutionary Genomics over 90 days. Evolutionary Genomics is related to or competes with John Wiley, Envista Holdings, Bright Scholar, Weyco, Douglas Emmett, InfuSystems Holdings, and Universal Technical. Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively se... More
Evolutionary Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Evolutionary Genomics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Evolutionary Genomics upside and downside potential and time the market with a certain degree of confidence.
Evolutionary Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evolutionary Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Evolutionary Genomics' standard deviation. In reality, there are many statistical measures that can use Evolutionary Genomics historical prices to predict the future Evolutionary Genomics' volatility.Evolutionary Genomics Backtested Returns
We have found three technical indicators for Evolutionary Genomics, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Evolutionary Genomics are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Evolutionary Genomics has perfect predictability. Overlapping area represents the amount of predictability between Evolutionary Genomics time series from 28th of April 2025 to 12th of June 2025 and 12th of June 2025 to 27th of July 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Evolutionary Genomics price movement. The serial correlation of 1.0 indicates that 100.0% of current Evolutionary Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Evolutionary Genomics lagged returns against current returns
Autocorrelation, which is Evolutionary Genomics pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Evolutionary Genomics' pink sheet expected returns. We can calculate the autocorrelation of Evolutionary Genomics returns to help us make a trade decision. For example, suppose you find that Evolutionary Genomics has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Evolutionary Genomics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Evolutionary Genomics pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Evolutionary Genomics pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Evolutionary Genomics pink sheet over time.
Current vs Lagged Prices |
| Timeline |
Evolutionary Genomics Lagged Returns
When evaluating Evolutionary Genomics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Evolutionary Genomics pink sheet have on its future price. Evolutionary Genomics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Evolutionary Genomics autocorrelation shows the relationship between Evolutionary Genomics pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Evolutionary Genomics.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.